Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Vancomycin Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

67 API Suppliers, 20 USDMF, 16 CEP/COS, 7 JDMF, 1 EU WC, 17 KDMF, 20 NDC API, 28 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

69 Drugs in Development

69 Drugs in Development

FINISHED DOSAGE FORMULATIONS

370 FDF Dossiers, 151 FDA Orange Book, 96 Europe, 30 Canada, 20 Australia, 15 South Africa, 58 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 1.25GM BASE/VIAL, POWDER;INTRAVENOUS - EQ 1.5GM BASE/VIAL, POWDER;INTRAVENOUS - EQ 1.75GM BASE/VIAL, POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 2GM BASE/VIAL, POWDER;INTRAVENOUS - EQ 750MG BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 1.25GM BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 1.5MG BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 10GM BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 1GM BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 500MG BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 5GM BASE/VIAL, POWDER;INTRAVENOUS, ORAL - EQ 750MG BASE/VIAL, CAPSULE;ORAL - EQ 125MG BASE, CAPSULE;ORAL - EQ 250MG BASE

RELATED EXCIPIENT COMPANIES

7 DKSH, 2 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 4 ACG Worldwide, 6 Actylis, 14 BASF, 1 Esteem Industries, 2 Finar, 2 Gangwal Chemicals, 3 Lonza Capsugel, 2 Nomisma Healthcare, 1 Pluviaendo, 1 Qualicaps, 6 Roquette, 1 Seppic, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

13 Topical, 9 Coating Systems & Additives, 9 Thickeners and Stabilizers, 8 Empty Capsules, 7 Parenteral, 6 Fillers, Diluents & Binders, 6 Solubilizers, 6 Film Formers & Plasticizers, 5 Controlled & Modified Release, 4 Granulation, 3 Coloring Agents, 3 Taste Masking, 3 Lubricants & Glidants, 1 Surfactant & Foaming Agents, 1 Direct Compression, 1 Emulsifying Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 98 News #PharmaBuzz

GLOBAL SALES INFORMATION

36 US Medicaid Prescriptions, 51 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

46 APIs, 20 FDF Dossiers

PATENTS & EXCLUSIVITIES

67 US Patents

67 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 2 Others

ANALYTICAL

1 Analytical Methods

1 Analytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Abbott Laboratories	U.S.A	ABBOTT LABORATORIES Abbott Park US	R1-CEP 1997-063 - Rev 01	Vancomycin hydrochloride	2009-06-04	Withdrawn by Holder	Chemical	2012-08-10	1058
29/11/2025	Chongqing DaXin Pharmaceutical	China	CHONGQING DAXIN PHARMACEUTICAL CO., LTD. Shuitu Town CN	CEP 2018-197 - Rev 01	Vancomycin hydrochloride	2025-05-05	Valid	Chemical and TSE		1058

Vancomycin Hydrochloride

Vancomycin Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

67 API Suppliers

20 USDMF

16 CEP/COS

7 JDMF

1 EU WC

17 KDMF

20 NDC API

28 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

69 Drugs in Development

FINISHED DOSAGE FORMULATIONS

370 FDF Dossiers

151 FDA Orange Book

96 Europe

30 Canada

20 Australia

15 South Africa

58 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 1.25GM BASE/VIAL

POWDER;INTRAVENOUS - EQ 1.5GM BASE/VIAL

POWDER;INTRAVENOUS - EQ 1.75GM BASE/VIAL

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAVENOUS - EQ 2GM BASE/VIAL

POWDER;INTRAVENOUS - EQ 750MG BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 1.25GM BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 1.5MG BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 10GM BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 1GM BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 500MG BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 5GM BASE/VIAL

POWDER;INTRAVENOUS, ORAL - EQ 750MG BASE/VIAL

CAPSULE;ORAL - EQ 125MG BASE

CAPSULE;ORAL - EQ 250MG BASE

RELATED EXCIPIENT COMPANIES

7 DKSH

2 Nanjing Well Pharmaceutical

1 Kirsch Pharma

4 ACG Worldwide

6 Actylis

14 BASF

1 Esteem Industries

2 Finar

2 Gangwal Chemicals

3 Lonza Capsugel

2 Nomisma Healthcare

1 Pluviaendo

1 Qualicaps

6 Roquette

1 Seppic

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

13 Topical

9 Coating Systems & Additives

9 Thickeners and Stabilizers

8 Empty Capsules

7 Parenteral

6 Fillers, Diluents & Binders

6 Solubilizers

6 Film Formers & Plasticizers

5 Controlled & Modified Release

4 Granulation

3 Coloring Agents

3 Taste Masking

3 Lubricants & Glidants

1 Surfactant & Foaming Agents

1 Direct Compression

1 Emulsifying Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

98 News #PharmaBuzz

GLOBAL SALES INFORMATION

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons